Clinical value of calprotectin in sepsis and severe infections
27. Jul 2020 |
5 min read
Calprotectin for early detection and monitoring
The increase in calprotectin concentration is one of the fastest indicators of an inflammatory and/or infectious process. This suggests the role of calprotectin as a useful biomarker for early detection and monitoring of sepsis and severe infections [1,2]. Since the concentration of calprotectin reflects the severity of the disease, monitoring calprotectin also allows surveillance of disease development [3,4].
Calprotectin’s early response to inflammation and infections combined with turbidimetric technology provides fast information and results on the patient’s inflammatory response and infection status.
Promising biomarker for diagnosis of bacterial infections and sepsis
Studies are showing that calprotectin is one of the earliest indicators of inflammation and infection [1,2]. Calprotectin has, in addition, also shown high clinical value as an early biomarker of bacterial infection in critically ill patients . Calprotectin is therefore a promising biomarker for bacterial infections, and clinical studies indicate the biomarker to be superior to Heparin-binding Protein (HBP) and Procalcitonin (PCT) in differentiating between bacterial and viral infections [5,6].
The levels of plasma calprotectin have shown to be significantly higher in septic patients and non-survivors. Furthermore, calprotectin has also performed better than PCT and HBP in the diagnosis of sepsis, including in distinguishing between sepsis patients and trauma patients .
Prediction of severe events in clinical sepsis
Sepsis is the most frequent cause of admission and the most common cause of death in intensive care units (ICUs). Rapid and correct diagnosis is very important in sepsis, as any delay in treatment will increase mortality. Since sepsis is often associated with non-specific symptoms it is difficult to diagnose . In addition, prediction of severe events in clinical sepsis is challenging and of great importance for correct treatment and care of the affected patients.
Calprotectin has shown to be a useful biomarker for prediction of early severe events in sepsis. A recent study at Karolinska Hospital in Stockholm has shown that the level of plasma calprotectin is significantly higher in sepsis patients who subsequently developed severe events.
The study also indicates that plasma calprotectin performs better than traditional biomarkers such as PCT, neutrophil-lymphocyte-ratio and C-reactive protein (CRP) for prediction of severe events in sepsis patients .
The value of calprotectin in infection
Differentiates between bacterial and viral infections [5,6]
Predicts serious events in critically ill patients [4,9]
Superior to traditional biomarkers for prediction of severe events in clinical sepsis 
Gentian Calprotectin (GCAL®) Immunoassay
Calprotectin’s early response to inflammation and infections will, combined with turbidimetric technology, provide faster information and results on patient’s inflammatory response and infection status. GCAL® has therefore potential applications for early detection and monitoring of sepsis and other severe bacterial infections, when it is critical to get access to the results as soon as possible. Since GCAL® is a Particle-Enhanced Turbidimetric Immunoassay (PETIA), the assay is rapidly performed in only 10 minutes. The immunoassay can be applied on a wide range of automated clinical chemistry analysers, and it is developed and manufactured by Gentian.
For more details on Gentian Calprotectin Immunoassay please contact us email@example.com fill out the form below:
Lipcsey et al. Innate Immun. 2019 Aug;25(6):369-373
Fullerton et al. Meeting abstracts, Critical Care 2020, 24(Suppl 1):87
Gao et al. Am J Emerg Med. 2015;33(9):1278–1282
Jonsson et al. Crit Care Resusc. 2017 Sep;19(3):205-213
Havelka et al. Sci Rep. 2020 Mar 6;10(1):4208
Bartáková et al. Diagn Microbiol Infect Dis. 2019 Mar;93(3):219-226
Larsson et al. Scand J Clin Lab Invest. 2020 Feb - Apr;80(2):156-161
Kaukonen KM et al. N Engl J Med. 2015;372(17):1629–1638
Parke et al. Meeting abstracts, Critical Care 2020, 24(Suppl 1):87